FORMULA 1- atp, adeps suillus, adrenal cortex suis, alpha ketoglutaricum acidum, cerebrum suis, coenzyme a, colon suis, duodenum United States - English - NLM (National Library of Medicine)

formula 1- atp, adeps suillus, adrenal cortex suis, alpha ketoglutaricum acidum, cerebrum suis, coenzyme a, colon suis, duodenum

20lighter, llc. - adenosine triphosphate (unii: 8l70q75fxe) (adenosine triphosphate - unii:8l70q75fxe), lard (unii: si6o3iw77z) (lard - unii:si6o3iw77z), sus scrofa cerebrum (unii: 4gb5dqr532) (sus scrofa cerebrum - unii:4gb5dqr532), coenzyme a (unii: saa04e81ux) (coenzyme a - unii:saa04e81ux), sus scrofa colon (unii: 94j255a0uc) (sus scrofa colon - unii:94j255a0uc), sus scrofa duodenum (unii: p6j2sft80o) (sus scrofa duodenum - unii:p6j2sft80o), bos taurus bile (unii: et3651zlou) (bos taurus bile - unii:et3651zlou), f - uses: for the temporary relief of symptoms of food cravings, including: constant appetite, increased or insatiable hunger.*

Mucosa Compositum tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mucosa compositum tabl.

heel belgium sa-nv - argentum nitricum 1 mg; atropa bella-donna 1 mg; ceanothus americanus 1 mg; hydrastis canadensis 1 mg; psychotria ipecacuanha 1 mg; kalium bichromicum 1 mg; lachesis 1 mg; mandragora e radice siccata l., dried roots 1 mg; mucosa coli suis 1 mg; mucosa ductus choledochi suis 1 mg; mucosa ilei suis 1 mg; mucosa jejuni suis 1 mg; mucosa nasalis suis 1 mg; mucosa oculi suis 1 mg; mucosa oesophagi suis 1 mg; mucosa oris suis 1 mg; mucosa pulmonis suis 1 mg; mucosa pylori suis 1 mg; mucosa rectalis suis 1 mg; mucosa vesicae felleae suis 1 mg; mucosa vesicae urinariae suis 1 mg; strychnos nux-vomica 1 mg; oxalis acetosella 1 mg; pancreas suis 1 mg; phosphorus 1 mg; pulsatilla pratensis 1 mg; sulfur. 1 mg; veratrum album 1 mg; marsdenia cundurango rchb f., dried cortex from stems and branches 1 mg; anacardium orientale l., dried fruit 1 mg; kreosotum 1 mg; momordica balsamina l., fresh fruits 1 mg; mucosa duodeni suis 1 mg; ventriculus suis 1 mg - tablet

INDYLON 25MG CAPSULE,HARD Cyprus - English - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

indylon 25mg capsule,hard

POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE- potassium chloride, dextrose monohydrate and sodium chloride injection, solu United States - English - NLM (National Library of Medicine)

potassium chloride in dextrose and sodium chloride- potassium chloride, dextrose monohydrate and sodium chloride injection, solu

baxter healthcare corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - potassium chloride 150 mg in 100 ml - potassium chloride in dextrose and sodium chloride injection is indicated as a source of water, electrolytes and calories. potassium chloride in dextrose and sodium chloride injection is contraindicated in patients with: risk summary appropriate administration of potassium chloride in dextrose sodium chloride injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with potassium chloride in dextrose sodium chloride injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary sodium and potassium are present in human breast milk. there are no data on the effects

POTASSIUM CHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

potassium chloride injection, solution

baxter healthcare corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride 29.8 g in 1000 ml - potassium chloride injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. this highly concentrated, ready-to-use potassium chloride injection is intended for the maintenance of serum k+ levels and for potassium supplementation in fluid restricted patients who cannot accommodate additional volumes of fluid associated with potassium solutions of lower concentration. when using these products, these patients should be on continuous cardiac monitoring and frequent testing for serum potassium concentration and acid-base balance. potassium chloride injection is contraindicated in patients with:

POTASSIUM CHLORIDE IN DEXTROSE- potassium chloride and dextrose monohydrate injection, solution United States - English - NLM (National Library of Medicine)

potassium chloride in dextrose- potassium chloride and dextrose monohydrate injection, solution

baxter healthcare corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - potassium chloride 150 mg in 100 ml - potassium chloride in dextrose injection is indicated as a source of water, electrolytes and calories. potassium chloride in dextrose injection is contraindicated in patients with: risk summary appropriate administration of potassium chloride in dextrose injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with potassium chloride in dextrose injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary potassium is present in human breast milk. there are no data on the effects of potassium chloride in dextrose injection on a breastfed infant or the effects on

Potassium Chloride 0.15 % w/v and Glucose 5% w/v Solution for Infusion BP Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 0.15 % w/v and glucose 5% w/v solution for infusion bp

baxter holding b.v. - potassium chloride; glucose - solution for infusion - 0.15/5 percent weight/volume - electrolyte solutions; potassium chloride

Potassium Chloride 0.3% w/v & Sodium Chloride 0.9% w/v Solution for Infusion BP Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 0.3% w/v & sodium chloride 0.9% w/v solution for infusion bp

baxter holding b.v. - potassium chloride; sodium chloride - solution for infusion - 0.3 % w/v + 0.9 percent weight/volume - electrolyte solutions; potassium chloride

POTASSIUM CHLORIDE- potassium chloride injection United States - English - NLM (National Library of Medicine)

potassium chloride- potassium chloride injection

fresenius kabi usa, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. this highly concentrated, ready-to-use potassium chloride injection is intended for the maintenance of serum k + levels and for potassium supplementation in fluid restricted patients who cannot accommodate additional volumes of fluid associated with potassium solutions of lower concentration. when using these products, these patients should be on continuous cardiac monitoring and frequent testing for serum potassium concentration and acid-base balance. potassium chloride injection is contraindicated in patients with: - hyperkalemia - known hypersensitivity to potassium chloride injection check flexible container solution composition, lot number, and expiry date. do not remove solution container from its overwrap until immediately before use. use sterile equipment and aseptic technique. see precautions for information on the avoidance of air embolism. to open - turn solution container over so that the text is face down. using the pre-cut corner tabs, peel open the overwrap and remove solution container. - check the solution container for leaks by squeezing firmly. if leaks are found, or if the seal is not intact, discard the solution. - do not use if the solution is cloudy or a precipitate is present. preparation for administration - immediately before inserting the infusion set, break off blue infusion port cap with the arrow pointing away from container. - use a non-vented infusion set or close the air-inlet on a vented set. - close the roller clamp of the infusion set. - hold the base of blue infusion port. - insert spike through blue infusion port by rotating wrist slightly until the spike is inserted. note: see full directions accompanying administration set. warning: do not use flexible container in series connections. manufactured for: lake zurich, il 60047 made in norway www.fresenius-kabi.com/us 451699b revised: september 2023 01-59-16-006b

BAXTER POTASSIUM CHLORIDE 40 mmol and 0.9% SODIUM CHLORIDE 100 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 40 mmol and 0.9% sodium chloride 100 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 29.8 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.